NOVEL TECHNOLOGY

At the Forefront of Innovation

We are developing an innovative long-acting cervical barrier device with the high effectiveness of the IUDs without their side effects.

THE UNMET NEED

Women Deserve More Options

45% of pregnancies in the US are unplanned. The rate of unplanned pregnancies in the US dropped by only 1.7% between 2010 and 2019.

36% of women in the US report they have experienced at least 1 unplanned pregnancy.

30% of US maternal deaths result from unplanned pregnancies. The US has the highest maternal mortality rate among high-income countries, with 688 pregnancy-related deaths in 2024.

91% of women in the US report that no available contraceptive method offers the combination of attributes they desire.

73% of women in the US want a birth control method that is highly effective and has few or no side effects. This does not exist today.

WHAT WE WANT TO OFFER ALL WOMEN

Low-To-No Side Effects

Hormone-Free

Does not contain any synthetic hormones and does not cause hormonal side effects

Copper-Free

Not associated with the side effects common with the copper IUD and is not toxic

No Menstrual Changes

Not expected to change bleeding patterns nor cause spotting

Set-It-And-Forget-It

Long-Acting

Expected to last several years before needing to be replaced

Reversible

Fertility will return to normal immediately after the device is removed

Forgettable

Discreetly worn in the cervix without interfering with intercourse and without regular maintenance

Accessible & Acceptable

Fitted to The User

Inserted by any trained medical professional without triggering IUD pain points in the uterus

Affordable Option

Designed to be low-cost and accessible for patients who do not have insurance coverage

Self-Removable Option

Designing a 2nd generation device with user-controlled removal to give women more autonomy

LARGE MARKET SIZE

Growing Demand & Market Opportunity

$2B

US IUD Market

13M IUD users in the US

$10B

US Contraceptive Market

80M birth control users in the US

$36B

Global Contraceptive Market

1B birth control users worldwide 

GLOBAL MARKET INSIGHTS RREPORT 2023-2032 (2030)

ROADMAP TO MARKET

Completing Our Preclinical Development Toward Clinical Studies

  • Concept & Design

    An unmet need is identified. Concepts are generated and researched for proof-of-concept.

  • Preclinical Research

    Prototypes are tested in non-clinical settings, such as in animals and fresh excised human tissues.

  • Pilot & Pivotal Trials

    Devices are tested in humans, first in a small clinical trial and then a larger trial, for safety and efficacy.

  • Regulatory Approval

    Clinical data is thoroughly examined by regulatory bodies to determine if the device will be approved.

  • Product Launch

    The approved device becomes available to providers and patients. Safety will continue to be monitored.

RESEARCH OVERVIEW

De-Risking Our Technology

  • OB/GYN counseling patient

    Cervical Study

    In an ongoing clinical study, we have demonstrated low discomfort levels associated with cervical device placement (average of 1.3 on a pain scale of 10) in 6 nulliparous women (who have not had a vaginal delivery).

    Click Here

  • Pilot Baboon Study

    In a 2-week pilot study in baboons, our device was safely and tolerably worn through menses. We did not observe any changes in animal behavior, microbiome, inflammation, or tissue pathology.

    Make It

  • Hysterectomy Study

    We have tested our device in 25+ excised human tissues after they are removed from patients undergoing hysterectomies. We have demonstrated fit, retention and ease of insertion and retrieval.

    Click Here

  • In Vitro Efficacy Study

    We have shown complete blockage of human sperm from 10 donors and of rat sperm with our device.

    Note: Rat sperm are smaller than human sperm!

    Click Here

  • Functional Testing

    We tested the performance of our device with hyper-realistic anatomical models and with simulated fluids, including artificial menstrual fluid, simulated mucus, and simulated seminal fluid.

    Make It

  • Product Market Fit

    We have spoken with 50+ medical professionals and 50+ women and people who have used birth control, and we validated the unmet need for more non-hormonal and copper-free options.

    Make It

NIH & NSF SUPPORT DEMONSTRATING SCIENTIFIC RIGOR

Over $5M in Grant Funding To Date

OUR VISION

Women Deserve Better

As an impact-driven team, we not only want to deliver a solution directly designed for 73% of women in the US, we want to ensure equitable access so all women and girls can achieve their reproductive goals.

Who We Are